Published in Cancer Gene Ther on February 01, 2000
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol (2009) 1.20
Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol (2003) 0.96
Safety and clinical usage of newcastle disease virus in cancer therapy. J Biomed Biotechnol (2011) 0.87
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel) (2013) 0.86
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines (2016) 0.77
Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine. Clin Dev Immunol (2011) 0.77
Induction of antitumor response to fibrosarcoma by Newcastle disease virus-infected tumor vaccine. Med Oncol (2017) 0.75
The requirement of more than one antigenic determinant for immunogenicity. J Exp Med (1969) 5.61
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 4.20
The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci (2000) 3.70
Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17
Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential. Immunity (2000) 2.93
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res (1998) 2.44
Human (HLA-A and HLA-B) and murine (H-2K and H-2D) histocompatibility antigens are cell surface receptors for Semliki Forest virus. Proc Natl Acad Sci U S A (1978) 2.41
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest (1996) 2.10
Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol (1998) 2.09
Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res (1983) 2.04
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum (2006) 1.96
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med (2001) 1.88
Cell migration strategies in 3-D extracellular matrix: differences in morphology, cell matrix interactions, and integrin function. Microsc Res Tech (1998) 1.86
T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest (2000) 1.85
Metastatic potential severely altered by changes in tumor cell adhesiveness and cell-surface sialylation. J Exp Med (1983) 1.84
Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol (2000) 1.82
Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res (2001) 1.82
Amoeboid leukocyte crawling through extracellular matrix: lessons from the Dictyostelium paradigm of cell movement. J Leukoc Biol (2001) 1.78
A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes. J Immunol (1985) 1.76
Hailey-Hailey disease. Eradication by dermabrasion. Arch Dermatol (1994) 1.73
Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res (2000) 1.67
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res (2001) 1.59
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer (1994) 1.53
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52
Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res (2000) 1.51
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin. Nature (1982) 1.48
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo. Int J Cancer (1979) 1.48
Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res (1999) 1.46
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature (1976) 1.45
Immune responses against native and chemically modified albumins in mice. I. Analysis of non-thymus-processed (B) and thymus-processed (T) cell responses against methylated bovine serum albumin. J Exp Med (1972) 1.45
Should elective lymph node dissection be used for treatment of primary melanoma? J Cancer Res Clin Oncol (1989) 1.44
H-2-like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection. Nature (1976) 1.43
EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev (1993) 1.43
Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer (1987) 1.41
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol (2004) 1.39
Anorectal melanoma: surgical management guidelines according to tumour thickness. Br J Cancer (2003) 1.37
Determination of antibody class in a system of cooperating antigenic determinants. J Exp Med (1970) 1.36
Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol Biol Cell (1999) 1.33
Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol (2000) 1.32
Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia (2006) 1.31
Immune responses against native and chemically modified albumins in mice. II. Effect of electric charge and conformation on the humoral antibody response and on helper T cell responses. J Immunol (1974) 1.31
Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med (1991) 1.29
Interactions of Fc receptors with antibodies against Ia antigens and other cell surface components. J Exp Med (1975) 1.27
Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv Cancer Res (1985) 1.27
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity (2001) 1.26
Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood (2001) 1.25
Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol (1996) 1.24
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol (1999) 1.24
Different patterns of lectin binding and cell surface sialylation detected on related high- and low-metastatic tumor lines. Cancer Res (1983) 1.24
Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol (2000) 1.24
Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res (1995) 1.24
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro. Int J Cancer (1979) 1.20
Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res (1997) 1.17
Simulation of the electrical and mechanical gradient of the small intestine. Am J Physiol (1968) 1.17
Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol (1993) 1.17
Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release. Blood (1999) 1.17
Induction of carcinoma cell migration on vitronectin by NF-kappa B-dependent gene expression. Mol Biol Cell (1995) 1.16
Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol (1999) 1.16
Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis. Oncogene (1995) 1.16
The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-alpha-induced expression of monocyte-chemoattractant protein-1 in endothelial cells. Blood (1999) 1.15
Listeria monocytogenes-infected human dendritic cells: uptake and host cell response. Infect Immun (2000) 1.14
Phylogeny and dating of some pathogenic keratinophilic fungi using small subunit ribosomal RNA. J Med Vet Mycol (1996) 1.14
Activation of nuclear factor-kappa B and gene expression in human endothelial cells by the common haptens nickel and cobalt. J Immunol (1995) 1.14
The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol (1997) 1.13
Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer (1985) 1.12
Merkel cell carcinoma--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol (2011) 1.12
A new sensitive assay for antibody against cell surface antigens based on inhibition of cell-dependent antibody-mediated cytotoxicity. I. Specificity and sensitivity. J Exp Med (1974) 1.11
IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol (2000) 1.11
Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci (1996) 1.11
Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology (1997) 1.11
Characterization and isolation of a trypsin-like serine protease from a long-term culture cytolytic T cell line and its expression by functionally distinct T cells. J Immunol (1986) 1.11
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes. Int J Cancer (1979) 1.10
Effective subunit vaccines against an enveloped animal virus. Nature (1978) 1.10
Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int Immunol (1994) 1.09
Antigenic variation in cancer metastasis: immune escape versus immune control. Cancer Metastasis Rev (1982) 1.09
Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant. Eur J Immunol (1982) 1.09
Migration of dendritic cells within 3-D collagen lattices is dependent on tissue origin, state of maturation, and matrix structure and is maintained by proinflammatory cytokines. J Leukoc Biol (2000) 1.08
Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells. Int J Cancer (1985) 1.08
Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis (1991) 1.07
Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. J Hosp Infect (2013) 1.07
Immunohistochemistry in the evaluation of melanocytic tumors. Semin Diagn Pathol (1993) 1.07
Hepatocyte-tumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti-H-2 antibody. J Exp Med (1980) 1.07
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res (2007) 1.06
Phenotype of normal cutaneous microvasculature. Immunoelectron microscopic observations with emphasis on the differences between blood vessels and lymphatics. J Invest Dermatol (1996) 1.05
Migration of dendritic cells in 3D-collagen lattices. Visualisation of dynamic interactions with the substratum and the distribution of surface structures via a novel confocal reflection imaging technique. Adv Exp Med Biol (1997) 1.05
Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol (2007) 1.04
Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology (1994) 1.04
Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol (2000) 1.04
Cytotoxic immune cells with specificity for defined soluble antigens. IV. Antibody as mediator of specific cytotoxicity. J Exp Med (1974) 1.04